| Identification | Back Directory | [Name]
Piperphentonamine | [CAS]
1623804-44-3 | [Synonyms]
Henagliflozin
Piperphentonamine
β-D-Glucopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-5-C-(hydroxymethyl)- | [Molecular Formula]
C22H24ClFO7 | [MOL File]
1623804-44-3.mol | [Molecular Weight]
454.87 |
| Hazard Information | Back Directory | [Uses]
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research[1]. | [in vivo]
Henagliflozin (SHR3824) (p.o., 0.1-3.0 mg/kg, once) improves glucose tolerance in a dose-dependent manner in normal mice after exposure to glucose challenge[1].
Henagliflozin (SHR3824) (p.o., 0.3-3.0 mg/kg, once daily, 41 days) increases urinary glucose excretion in a dose-dependent manner and significantly reduces blood glucose levels in GK rats, with no effect on body weight or food intake. The HbA1c values of GK rats treated with 0.3, 1.0 or 3.0 mg/kg are 5.47%, 5.19% and 5.04%, respectively[1].
Henagliflozin (SHR3824) (p.o., 0.3-3.0 mg/kg, once daily, 43 days) causes a dose-dependent increase in urinary output and urinary glucose excretion in db/db mice, with a concomitant decrease in plasma glucose levels and no effect on body weight or food intake. The doses of 0.3, 1.0 or 3.0 mg/kg results in significant reductions in non-fasting and fasting glucose levels of 24.7%, 28.2% or 35.1% and 49.5%, 57.8% or 62.9%, respectively[1].
| [References]
[1] Pang-ke Yan, et al. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models. Acta Pharmacol Sin. 2014 May;35(5):613-24. DOI:10.1038/aps.2013.196 |
|
|